Highlights Ascendis Pharma A/S

Equities

ASND

US04351P1012

Real-time Estimate Cboe BZX Other stock markets 02:40:08 2024-05-13 pm EDT			5-day change	1st Jan Change
133.2 ^USD	-0.21%		-1.07%	+5.25%

03:31pm	Ascendis Says Late-Stage Trial Shows 'Significant' Improvements in Kidney Function for Adults Treated With TransCon PTH	MT
May. 10	Paycom Software Insider Sold Shares Worth $503,551, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ascendis Says Late-Stage Trial Shows 'Significant' Improvements in Kidney Function for Adults Treated With TransCon PTH	09:31am	MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	May. 06	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	May. 03	MT
Ascendis Pharma Q1 Net Loss Widens, Revenue Rises	May. 03	MT
Ascendis Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Earnings Flash (ASND) ASCENDIS PHARMA Reports Q1 Revenue EUR95.9M	May. 02	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	Apr. 29	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	Apr. 26	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism	Apr. 24	MT
Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism	Apr. 24	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Apr. 18	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
Ascendis Pharma Q4 Net Loss Narrows, Revenue Rises	Feb. 07	MT
Earnings Flash (ASND) ASCENDIS PHARMA Posts Q4 Revenue EUR137.7M	Feb. 07	MT
Ascendis Pharma A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 07	CI
Ascendis Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 07	CI
Ascendis Pharma A/S Launches 2nd TransCon Product: YORVIPATH Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism	Jan. 31	CI
Ascendis Spinning Off Ophthalmology Assets into Eyconis with Venture Firms Backing	Jan. 29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ascendis Pharma A/S

Equities

ASND

US04351P1012

Highlights

Filters